clopidogrel has been researched along with thrombin receptor peptide (42-55) in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gebauer, MU; Haeberli, A; Julmy, F; Meyer, BJ; Moshfegh, K; Redondo, M; Wuillemin, WA | 1 |
| Elisaf, M; Goudevenos, JA; Mitsios, JV; Papathanasiou, AI; Rodis, FI; Tselepis, AD | 1 |
| Elisaf, M; Goudevenos, JA; Mitsios, JV; Papathanasiou, AI; Tselepis, AD | 1 |
2 trial(s) available for clopidogrel and thrombin receptor peptide (42-55)
| Article | Year |
|---|---|
Antiplatelet effects of clopidogrel compared with aspirin after myocardial infarction: enhanced inhibitory effects of combination therapy.
Topics: Adenosine Diphosphate; Adult; Aged; Antigens, CD; Aspirin; Blood; Clopidogrel; Collagen; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dual Specificity Phosphatase 2; Humans; Middle Aged; Myocardial Infarction; P-Selectin; Peptide Fragments; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Membrane Glycoproteins; Prospective Studies; Protein Phosphatase 2; Protein Tyrosine Phosphatases; Tetraspanin 30; Ticlopidine | 2000 |
Atorvastatin does not affect the antiplatelet potency of clopidogrel when it is administered concomitantly for 5 weeks in patients with acute coronary syndromes.
Topics: Acute Disease; Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Atorvastatin; CD40 Ligand; Clopidogrel; Combined Modality Therapy; Coronary Disease; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Administration Schedule; Drug Interactions; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inactivation, Metabolic; Male; Middle Aged; P-Selectin; Peptide Fragments; Platelet Aggregation; Platelet Aggregation Inhibitors; Pravastatin; Pyrroles; Stents; Ticlopidine; Treatment Outcome | 2004 |
1 other study(ies) available for clopidogrel and thrombin receptor peptide (42-55)
| Article | Year |
|---|---|
The inhibitory potency of clopidogrel on ADP-induced platelet activation is not attenuated when it is co-administered with atorvastatin (20 mg/day) for 5 weeks in patients with acute coronary syndromes.
Topics: Acute Disease; Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Atorvastatin; Blood Platelets; CD40 Ligand; Cholesterol; Cholesterol, LDL; Clopidogrel; Coronary Disease; Drug Administration Schedule; Drug Interactions; Female; Flow Cytometry; Heptanoic Acids; Humans; Male; Middle Aged; P-Selectin; Peptide Fragments; Platelet Aggregation; Platelet Aggregation Inhibitors; Pyrroles; Ticlopidine; Triglycerides | 2005 |